Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Endocrine, Metabolic and Immune Disorders - Drug Targets is Scopus-indexed (Q3, CiteScore 4.1), WoS SCIE. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1871-5303Verify ISSN ↗2212-3873Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 129 / 250 | 48th | Q3 |
| Immunology and Allergy | 136 / 234 | 42nd | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q3, CiteScore 4.1.
Endocrine, Metabolic and Immune Disorders - Drug Targets is Q3 in Endocrinology, Diabetes and Metabolism (rank 129 of 250) and Q3 in Immunology and Allergy (rank 136 of 234), by CiteScore 2025.
Endocrine, Metabolic and Immune Disorders - Drug Targets is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.1, which places it in quartile Q3 at the 48th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.552, quartile Q3, with an H-index of 69.
Endocrine, Metabolic and Immune Disorders - Drug Targets is published by Bentham Science Publishers. Its print ISSN is 1871-5303 and its online ISSN is 2212-3873.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Endocrine, Metabolic and Immune Disorders - Drug Targets has an h-index of 67 and a 2-year mean of 1.43 citations per paper (OpenAlex). Its Scopus CiteScore is 4.1, quartile Q3. On 2-year citations it ranks #156 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
Endocrine, Metabolic and Immune Disorders - Drug Targets published 191 papers in 2025; its busiest recent year was 2020 with 290. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (69.2%), Italy (6.9%) and Iran (3.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.